Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics

Suberoylanilide hydroxamic acid (SAHA), a pan HDAC inhibitor, has been approved by the Food and Drug Administration (FDA) to treat cutaneous T cell lymphoma (CTCL). Nevertheless, the mechanisms underlying the therapeutic effects of SAHA on tumors are yet not fully understood. Protein phosphorylation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Cell Dev Biol
Main Authors: Huang, Huichao, Fu, Ying, Zhang, Ye, Peng, Fang, Lu, Miaolong, Feng, Yilu, Chen, Lin, Chen, Zhuchu, Li, Maoyu, Chen, Yongheng
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Cell and Developmental Biology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7726116/
https://ncbi.nlm.nih.gov/pubmed/33324635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2020.577784
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados